Black Diamond Therapeutics (BDTX) Liabilities and Shareholders Equity (2018 - 2026)

Black Diamond Therapeutics' Liabilities and Shareholders Equity history runs 9 years deep, the most recent figure standing at $132.9 million for Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 24.58% year-over-year to $132.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $600.0 million (up 2.26% YoY) and the FY2025 annual result came in at $143.0 million, up 16.61% from the prior year.
• Liabilities and Shareholders Equity was $132.9 million for Q1 2026 at Black Diamond Therapeutics, down from $143.0 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $219.5 million in Q1 2022 and bottomed at $119.9 million in Q2 2023.
• A 5-year average of $157.1 million and a median of $156.3 million in 2022 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity sank 39.71% — and 2024, when it increased 25.11%.
• Black Diamond Therapeutics' Liabilities and Shareholders Equity stood at $156.3 million in 2022, then rose by 1.48% to $158.6 million in 2023, then fell by 22.66% to $122.6 million in 2024, then gained by 16.61% to $143.0 million in 2025, then dropped by 7.05% to $132.9 million in 2026.
• Business Quant data shows BDTX's Liabilities and Shareholders Equity at $132.9 million in Q1 2026, $143.0 million in Q4 2025, and $157.7 million in Q3 2025.